Advocates Light a Path for Better Cancer Care in PH

Advocates from various organizations gathered to light a path towards better cancer care at an event held last March 10 at Greenbelt 3. (From Left:  Philippine Alliance of Patient Organizations President Fatima “Girlie” Lorenzo; Program Host Jing Castaneda; Patient Advocate Jojo Flores; MSD Philippines Market Access and Corporate Affairs Director Michael Andrew Blanch; MSD Philippines President and Managing Director Andreas Riedel; Cancer Commission Philippine College of Surgeons Director Dr. Ramy Roxas; Singer/Actor Marlo Mortel; MSD Philippines Business Unit Director Oncology Allan Ancheta; Department of Health Program Manager Dr. Clar Cairo; Greenbelt 3 Mall Senior Marketing Associate Manager Natasha Faustino; PHAP Executive Director Ted Padilla; Philippine Society of Medical Oncology President Dr. Arnold John Uson; National Council on Disability Affairs Executive Director Engr. Emer Rojas; and UHC Policy Development Senior Vice President Dr. Israel Pargas)

Health advocates gathered to call for better cancer care in the Philippines through a candle-lighting ceremony held last March 10 at the Greenbelt Activity Area in Makati City.  

Breakthrough treatment possible new mainstay against lung cancer

Breakthrough treatment possible new mainstay against lung cancer Immunotherapy drug outperforms chemo in latest trial

A recent study comparing the immunotherapy drug pembrolizumab to chemotherapy could alter more than 30 years of practice in lung cancer treatment.

The clinical trial, known as Keynote-024 (KN-024), showed pembrolizumab’s superiority in preventing cancer progression and prolonging the lives of previously untreated patients with non-small cell lung cancer (NSCLC).

Breakthrough treatment possible new mainstay against lung cancer

Immunotherapy drug outperforms chemo in latest trial

A recent study comparing the immunotherapy drug pembrolizumab to chemotherapy could alter more than 30 years of practice in lung cancer treatment.

The clinical trial, known as Keynote-024 (KN-024), showed pembrolizumab’s superiority in preventing cancer progression and prolonging the lives of previously untreated patients with non-small cell lung cancer (NSCLC).

New Breakthrough In Treating Lung Cancer Now In The Country!

Hopeless cases no more: Immunotherapy drug for advanced stages of lung cancer and melanoma now in the Philippines

An educational article sponsored by MSD

The spark of hope has never been brighter for Filipino patients with advanced stages of lung cancer and melanoma. MSD in the Philippines, a leader in oncology research and development just introduced immunotherapy, one of the most innovative cancer treatment methods to date.